Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein - PubMed (original) (raw)
Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein
M Lindh et al. Neurosci Lett. 1997.
Abstract
Apolipoprotein E (apoE) levels were compared in cerebrospinal fluid (CSF) taken on two occasions, with an average 15 months follow up, from groups of patients with Alzheimer's disease (AD: n = 18), mild cognitive impairment (MCI; n = 9) and other dementia disorders (ODD; n = 9). In these groups, CSF apoE levels were between 2-3-fold higher than values for a group of 27 healthy age-matched controls. CSF apoE levels in the AD group were significantly increased at follow up, compared to levels obtained on the first sampling occasion. For the same cases it had been shown previously that CSF tau protein levels were increased at follow up [Blomberg, M., Jensen, M., Basun, H., Lannfelt, L. and Wahlund, L-O., Neurosci. Lett., 214 (1996) 163-166]. The AD, but not MCI, ODD or control groups, also showed statistically significant correlations between CSF apoE and tau protein levels at both the first (r = 0.585, P < 0.01) and follow up (r = 0.695, P > 0.001 ) samplings. It is concluded that CSF measures of both apoE and tau may reflect an intimate relationship between these two proteins in AD and could prove useful in monitoring the progression of this condition.
Similar articles
- Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up.
Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Blomberg M, et al. Neurosci Lett. 1996 Aug 23;214(2-3):163-6. doi: 10.1016/0304-3940(96)12905-0. Neurosci Lett. 1996. PMID: 8878109 - Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Lautner R, et al. JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060. JAMA Psychiatry. 2014. PMID: 25162367 - Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease.
Zimetti F, Caffarra P, Ronda N, Favari E, Adorni MP, Zanotti I, Bernini F, Barocco F, Spallazzi M, Galimberti D, Ricci C, Ruscica M, Corsini A, Ferri N. Zimetti F, et al. J Alzheimers Dis. 2017;55(1):315-320. doi: 10.3233/JAD-160411. J Alzheimers Dis. 2017. PMID: 27662294 - Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease.
Arai H, Higuchi S, Sasaki H. Arai H, et al. Gerontology. 1997;43 Suppl 1:2-10. doi: 10.1159/000213879. Gerontology. 1997. PMID: 9187933 Review. - Links between ApoE, brain cholesterol metabolism, tau and amyloid beta-peptide in patients with cognitive impairment.
Leoni V, Solomon A, Kivipelto M. Leoni V, et al. Biochem Soc Trans. 2010 Aug;38(4):1021-5. doi: 10.1042/BST0381021. Biochem Soc Trans. 2010. PMID: 20658997 Review.
Cited by
- The role of high cholesterol in age-related COVID19 lethality.
Wang H, Yuan Z, Pavel MA, Jablonski SM, Jablonski J, Hobson R, Valente S, Reddy CB, Hansen SB. Wang H, et al. bioRxiv [Preprint]. 2021 Jun 28:2020.05.09.086249. doi: 10.1101/2020.05.09.086249. bioRxiv. 2021. PMID: 32511366 Free PMC article. Updated. Preprint. - Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.
Rösler N, Wichart I, Jellinger KA. Rösler N, et al. J Neural Transm (Vienna). 2001;108(2):231-46. doi: 10.1007/s007020170091. J Neural Transm (Vienna). 2001. PMID: 11314776 - Parental history of Alzheimer disease associated with lower plasma apolipoprotein E levels.
van Vliet P, Westendorp RG, Eikelenboom P, Comijs HC, Frölich M, Bakker E, van der Flier W, van Exel E. van Vliet P, et al. Neurology. 2009 Sep 1;73(9):681-7. doi: 10.1212/WNL.0b013e3181b59c2e. Neurology. 2009. PMID: 19720974 Free PMC article. - Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis.
Dhiman K, Blennow K, Zetterberg H, Martins RN, Gupta VB. Dhiman K, et al. Cell Mol Life Sci. 2019 May;76(10):1833-1863. doi: 10.1007/s00018-019-03040-5. Epub 2019 Feb 15. Cell Mol Life Sci. 2019. PMID: 30770953 Free PMC article. Review. - Genomic convergence and network analysis approach to identify candidate genes in Alzheimer's disease.
Talwar P, Silla Y, Grover S, Gupta M, Agarwal R, Kushwaha S, Kukreti R. Talwar P, et al. BMC Genomics. 2014 Mar 15;15(1):199. doi: 10.1186/1471-2164-15-199. BMC Genomics. 2014. PMID: 24628925 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous